Virazole Articles
Tokyo pharma stocks - week to December 3
5 December 2001
Japan approves S-P's HCV combination
22 November 2001
S-P's PEG-Intron/ribavirin combo works in relapses
15 November 2001
Infergen outdoes Rebetron in Phase IV study
15 November 2001
Long-term efficacy of Pegasys seen in HCV
15 November 2001
Maxim to initiate Ph II Ceplene trials
8 November 2001
Sales flat at Schering-Plough as manufacturing problems persist
23 October 2001
Enzon goes into profit in 4th qtr
22 August 2001
Roche, S-P resolve peginterferon dispute
13 August 2001
Stock Commentary - New York
9 August 2001
ICN Pharma earnings take a downturn
3 August 2001
FDA approves Rebetol as separate treatment
31 July 2001
Flat 2nd-qtr sales/EPS at Schering-Plough
25 July 2001
S-P looking for royalty refund from ICN
11 July 2001
Roche licenses hep C drug from ICN
3 July 2001
ISIS 14803 reduces viral load in Hep C patients
21 June 2001
Ceplene shows long-term activity in HCV
24 April 2001
Manufacturing woes hit Schering-Plough
18 April 2001
Maxim's Ceplene to enter major HCV trial
17 April 2001
PEGIntron indications extended in EU
29 March 2001
EU extends Remicade indications
7 February 2001
Schering-Plough EPS increases 14.7%
26 January 2001
ICN profit warnings for 2000 and 2001
23 January 2001
Roche to invest in ICN's Ribapharm
22 December 2000
ICN to license drugs to S-P to settle dispute
16 November 2000
ICN Pharma profits continue to climb
7 November 2000
S-P sales growth driven by Claritin
24 October 2000
ICN 2nd-qtr revenues pushing $200 million
7 August 2000
Schering-Plough net income up 16%
26 July 2000
Roche hep C combo launched in Germany
29 June 2000
Schering-Plough net income rises 16.5%
26 April 2000
Stock Commentary New York
9 March 2000
ICN revenues boosted by Rebetron
3 March 2000
ICN Pharma to boost R&D activities
16 February 2000
ICN Pharma set to spend more on R&D
27 January 2000
Schering-Plough files BLA for PEG-Intron
11 January 2000
ICN revenues benefit from Rebetron
9 November 1999
Schering-Plough strong sales boost EPS
22 October 1999
ICN Pharmaceuticals charged with misleading investors
19 August 1999
Rebetol launch in Germany
22 June 1999
Rebetron approved in EU
20 May 1999
Rebetron gets first-line approval in Canada
5 May 1999
Roferon A works with ribavirin in HCV
15 April 1999
Schering-Plough buys $27 mill of ICN stock
9 April 1999
Stock Commentary New York
11 March 1999
ICN hit by $230 million charge in Yugoslavia
8 March 1999
Enzon - improving the delivery and side effect profile of proven
20 January 1999
Rebetron Indications Expanded Into HCV
16 December 1998
AASLD Conference - Focus On HCV/HBV By Lehman
1 December 1998
Enzon's PEG-Intron A In Phase III For CML
23 November 1998
ICN Hit Hard By Crises in Eastern Europe & Russia
10 November 1998
Stock Commentary New York
29 October 1998
Healthy Third-Quarter Growth For US Drug Majors
22 October 1998
Solid Growth Forecast For Schering Plough
24 August 1998
S-P Files For Temodal In The USA
20 August 1998
Gemini's Antisense Drug For RSV
13 August 1998
Standard & Poor's Impressed With ICN
7 August 1998
Schering-Plough Files sNDA For Rebetron
18 June 1998
FDA Clears Rebetron, New Therapy For Hepatitis C
15 June 1998
Latest Wave Of US 1st Quarter Results
7 May 1998
Stock Commentary New York
7 May 1998
Hep C Drug Given Priority Status
22 January 1998
S-P Files NDA For Rebetol Plus Intron-A
11 December 1997
Atlantic's MP351 Better Than Ribavirin?
6 November 1997
3rd Qtr Revenues Up For US Drug & Biotech Firms
6 November 1997
Intron A Plus Ribavirin Improve HCV Outcome
25 September 1997
Net Income Flat At ICN In 1st Qtr
19 May 1997
Atlantic's 2-5A "May Be Better" Than Virazole
21 April 1997
ICN Pharmaceuticals: 3 Acquisitions In '96
17 March 1997
New Hepatitis Treatments Highlighted At ICAAC
7 October 1996
Trimeris' Fusion Inhibitor For HIV To Enter Trials Soon?
30 September 1996
ICN Wins Fraud Case, But Shareholders Press On
2 September 1996
Canada: "Overpricing" Of ICN's Virazole
5 August 1996
Canadian Drug Prices Down 1.75% In 1995
1 July 1996
Schering-Plough Chief Gives R&D Update
10 June 1996
ICN And Chairman Under Investigation
20 May 1996
Canada Seeks 75% Price Cut For Virazole
29 April 1996
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
